<DOC>
	<DOCNO>NCT01043575</DOCNO>
	<brief_summary>The primary objective study characterize rifapentine drug level patient TB relationship effectiveness treat TB adverse effect experience participant .</brief_summary>
	<brief_title>High Dose Rifapentine Pharmacokinetics , Tolerability Safety Dosage Rifapentine Treatment Tuberculosis</brief_title>
	<detailed_description>This one-period , non-blinded , multi-center pharmacokinetic substudy rifapentine rifampin patient tuberculosis enrol Tuberculosis Trials Consortium ( TBTC ) Study 29 . This PK substudy use convenience sample , i.e . restrict TBTC sit logistical capacity intensive pharmacokinetic sampling . These sit non-random selection patient . In addition intensive sample 60 patient PK study , patient receive rifapentine Study 29 eligible sparse PK sample part parent treatment protocol .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Rifapentine</mesh_term>
	<criteria>Any patient enrol TBTC Study 29 . Provision inform consent study . Willingness sample outpatient clinic admit General Clinical Research Center ( GCRC ) hospital one occasion â€¢ Severe anemia define hematocrit le 25 % ( recent value , measure within 30 day PK study ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>rifapentine , pharmacokinetics , pharmacodynamics , tuberculosis</keyword>
</DOC>